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Hepatitis B is preventable and hepatitis C is treatable even if still at a high cost; most people who are infected with
hepatitis B or C virus have not been screened yet and are unaware of their infections; and most countries,
especially developing countries, do not have a national plan to prevent and control viral hepatitis. The advent of
effective new treatments for hepatitis C has been an agent of change, allowing consideration of the feasibility of
eliminating that disease and accelerating the control of viral hepatitis generally. These facts inspired the Viral
Hepatitis Prevention Board (VHPB) to organize a meeting in London (8–9 June 2015) on innovative sources for
funding of viral hepatitis prevention and treatment in low- and middle-income countries. The main focus of the
meeting was to provide an overview of current health systems controlling viral hepatitis in low- and middle-income
countries (LMICs); to identify ways to increase political commitment and financial sustainability of viral hepatitis
prevention and control programmes in such countries; to identify potential funders and explore new funding
mechanisms; to discuss lessons learnt about funding other disease programmes; to investigate how to convince
and motivate decision-makers to fund viral hepatitis programmes in LMICs; to provide options for improving access
to affordable screening and treatment of viral hepatitis in LMICs; and to list the commitments required for funding
by donors, including governments, bilateral and multilateral organizations, non-traditional donors, development
banks, foundations, and commercial financial institutions.
To improve viral hepatitis prevention and treatment in LMICs participating hepatitis and financing experts identified
the most urgent needs. Data on burden of disease must be improved. Comprehensive hepatitis policies and
strategies should be drafted and implemented, and existing strategies and policies improved to increase access to
treatment and prevention. Strong political will and leadership should be generated, potential partners identified
and partnerships created. Potential funders and funding mechanisms have to be researched. The outcome of this
meeting was integrated in a VHPB project to investigate creative financing solutions to expand access to and
provision of screening and other preventive services, treatment and care of hepatitis B and C in LMICs. The report is
available on www.vhpb.org.
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a meeting in London (8–9 June 2015). Its purpose was
four-fold. First it sought to examine how to increase
financial sustainability of viral hepatitis prevention and
control programmes and to raise political commitment
to investing in viral hepatitis programmes in low- and
middle-income countries (LMICs). Secondly, it would
explore what lessons could be learnt from the funding of
other disease programmes. Thirdly, it aimed to identify,
or at least explore ways of identifying, potential funders
and new funding mechanisms. Finally, it wanted to
determine options for improving access to affordable
screening and treatment of viral hepatitis in LMICs. The
report reflects the presentations and discussions at the
meeting and is therefore not a comprehensive analysis of
the subject. It is recognized that viral hepatitis needs to
be part of a broader, holistic and integrated approach,
avoiding vertical programmes.Background
In 1992, the World Health Assembly (WHA) adopted
resolution WHA45.17 on immunization and vaccine
quality, urging Member States to introduce routine
hepatitis B vaccination. More than 90% of the World
Health Organization (WHO)’s 194 Member States have
done so [1, 2]. According to WHO, investment in hepa-
titis B vaccination could prevent an estimated 4.8 million
deaths between 2010 and 2020 in the 73 countries sup-
ported by the GAVI Alliance [3]. Large numbers of
adults remain chronically infected with hepatitis B virus
and are at risk of developing liver disease. For them, pro-
longed treatment is needed. Besides treatment, the major
remaining challenges are to improve coverage of the
birth dose of hepatitis B vaccine and to design good
prevention and control strategies for viral hepatitis in
LMICs.
For hepatitis C, the landscape is complex and rapidly
changing. The epidemiology of, and responses to, hepa-
titis C are diverse. Large numbers of people infected
with hepatitis C virus (HCV) are unaware of their infec-
tion. There is no vaccine, but recently licensed direct-
acting antiviral agents (DAAs) are described as a
“technological breakthrough”. They offer public health
gains, with sustained viral response suggesting cure in
more than 95% of cases within three months, and appar-
ently little risk of resistance or relapse. Medically there
is every reason to give treatment, but barriers remain,
including access to care and significant costs. So far, dis-
counts have been successfully negotiated in only a few
countries and regions, generic formulations are being
marketed, and tiered pricing is also expected to improve
the situation as a result of more competition among
pharmaceutical companies.Although the subject of viral hepatitis prevention and
control is receiving greater international attention, it
faces not only declining funding for public health gener-
ally and an economic climate of austerity and shrinking
budgets but also competition for funding and resources
for other public health problems. UNAIDS, for instance,
is facing a considerable funding gap. Governmental bud-
gets are being squeezed, for example, by the high costs
of medicines for cancer as well as the new DAAs for
hepatitis C. Moreover, widespread introduction of DAAs
creates other challenges, such as insufficient resources
(human and financial), budgetary concerns about treat-
ing all people with chronic hepatitis C as well as the lack
of solid data on the burden of disease, especially in
LMICs. High quality tests to diagnose infection HCV
and monitor response to therapy are widely available in
most parts of the world, but they are not readily avail-
able or affordable in LMICs. At governmental and insti-
tutional levels, from the European Commission to
governments of some LMICs, there is a lack of political
will and financial investment. Viral hepatitis specifically
and liver disease in general have been under-represented
in health policies and funding.
In many countries the general population and even
health professionals lack awareness about chronic viral
hepatitis. Surveillance and screening are poor, and health
systems’ capacity for preventive care and treatment is
inadequate. Access to diagnostic and treatment services,
where they exist, may be limited, with marginalized
subjects facing further obstacles as well as stigmatization
and discrimination. Approaches to control and preven-
tion of viral hepatitis vary markedly between countries,
and not many have developed realistic financial models
to promote complete programmes for vaccination and
disease elimination. Collaboration between governments
and financial modellers might overcome the argument
that lack of a financial model is a reason for not taking
action.
Burden of disease
The current burden of disease estimates indicate that
240 million people are chronically infected with hepatitis
B virus, resulting in nearly 686,000 deaths each year
from cirrhosis and liver cancer, and 130–150 million
people are chronically infected with HCV, with around
700,000 deaths a year [4].
Although the incidence of hepatitis C is not increasing
in many countries because of safer medical procedures
and needle-exchange programmes, the burden of cirrho-
sis and liver cancer will continue to rise because of the
long incubation of the disease. Mortality rates globally
for cirrhosis and liver cancer have been increasing stead-
ily for several years, reflecting infections acquired
decades ago. Mathematical modelling shows that the
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rising to a peak around the year 2030. The overall
burden of viral hepatitis, however, is underestimated
because all viral causes of liver disease are not combined.
Many estimates have under-represented the morbidity
and mortality due to infection with HBV and HCV
because cirrhosis and liver cancer were not included..
Besides rates, attention must be paid to absolute num-
bers; low rates of reported hepatitis cases in China and
India hide the fact that millions of people are ill with
viral hepatitis.
Treatment
The new DAAs for treatment of hepatitis C have trans-
formed prospects. According to some analyses they are
cost-effective [5], but they are widely considered expen-
sive (e.g. list price of about US$ 84,000 for treatment
with sofosbuvir in the USA) and not necessarily afford-
able. One study shows that over the next five years the
cost of treatment of all eligible patients in the USA
would amount to US$ 65 billion, before offsetting for
savings in care for hepatitis C [6]. These estimates must
be considered low given that only half HCV-infected
persons are diagnosed and even smaller proportions are
in care settings where HCV treatment is provided [7].
Through mandated discounts for US government pro-
grammes and competition among pharmaceutical com-
panies, the cost of treating HCV has declined. Recent
studies also indicate that there is a wide variety in list
price while net prices are lower and very similar between
the US and other developed markets but even with
discounted prices, significant budgetary impact from
HCV treatments can be expected [8]. In the UK, Na-
tional Health Service (NHS) England estimated that the
cost of treating 20,000 people would reach £1 billion
(not allowing for any negotiated discount) and recently
announced that it would set aside more money for treat-
ment with DAAs. The French Government negotiated
deals under which a course of treatment with sofosbuvir
will cost €41,000 (the cost for treating 200,000 infected
people will amount to some €800 million) and treatment
with the ledipasvir/sofosbuvir combination has been cut
to €46,000. Altogether, about 15,000 people were treated
in France in 2014.
Consideration of overall long-term medical costs will
need to take account of savings in treatment of hepatitis
C due to successful therapy with the new antivirals.
Many patients in developed countries with end-stage
liver disease, in many cases due to hepatitis C, need a
liver transplant. Unless action is taken to control hepa-
titis C, expensive as it may be in the short-term, total
long-term health care costs are likely to rise. At the
European level, the European Liver Patients Association
(ELPA) has used a model simulating the public budgetimpact of increasing treatment coverage with newest
DAAs in France and Romania [9] to show that investing
in the newest therapies is cost-effective, with short-term
costs off-set in the longer run.
Participants stressed the need to perceive HCV as a
community-acquired infection (rather than focusing on
the concept of risk groups), with nosocomial and iatro-
genic transmission important modes of transmission. In
South Asia the reuse of syringes was highlighted as a
major source of transmission (see for example [10]).
Health systems in LMICs
Viral hepatitis should not be seen in a vacuum; strength-
ening health systems is high on the international public
health agenda, including WHO’s programme of work
and the 2030 Agenda for Sustainable Development. For
viral hepatitis, like other public health diseases and con-
ditions improvements are called for, from the training of
medical students and health-care workers to screening
and delivery of care and treatment services. LMICs need
fully-costed strategies, policies and action plans (e.g. for
testing, diagnosis, screening/surveillance, education,
treatment and prevention) as well as training in health
economics. The associated funding for implementation
must be committed and sustainable. Surveillance and
health information systems are also vital, with sufficient
sensitivity to detect changing morbidity and mortality
rates.
In some countries, political commitment and govern-
mental leadership are evident, with written national
plans and mainly State funding for programmes. In
Pakistan, the Prime Minister took responsibility for a na-
tional prevention and control programme, and in
Georgia the Government has introduced free treatment,
held national workshops leading to national pro-
grammes, and collaborated with a pharmaceutical com-
pany. In other countries, the new DAAs are being
introduced with donor support. Most countries do not
have national plans and many lack surveillance and
monitoring plans. A survey among WHO Member
States notes that 37% countries have a plan and 29%
have a governmental unit dedicated to hepatitis preven-
tion and control [11]. The Pan American Health
Organization (PAHO), however, is developing a regional
plan of action for the prevention and control of viral
hepatitis for the period 2016–2019 [12]. After the meet-
ing1, the World Health Assembly adopted the global
health sector strategy on HIV, viral hepatitis and sexually
transmitted infections for the period 2016–2021 in reso-
lution WHA69.22 in May 2016 [13]. Following this
adoption the other WHO regions are executing or devel-
oping regional action plans. The viral hepatitis strategy
considers that elimination of hepatitis B and C is feasible
in the foreseeable future and sets out actions for
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contexts and priorities as well as support and technical
assistance for Member States.
Generally awareness of viral hepatitis is poor, and out-
of-pocket payments (ranging from 10 to 80% in some
countries) [14, 15] are necessary and pose a heavy bur-
den on poor populations. In all countries priorities are
distorted, with ad hoc resource allocations, cost-effective
interventions not applied at scale, while spending is
wasted on ineffective interventions despite scarce
resources and inequitable access driven by vested inter-
ests. In LMICs, the capacity for priority-setting is
limited.
Overall, the list of main obstacles to prevention and
control of viral hepatitis, and indeed effective, strong
and sustained health systems, is long. Challenges identi-
fied included funding (for testing and treatment) and the
disparity in funding between viral hepatitis and diseases
with higher profiles; shortage and lack of training of
health-care workers; low levels of knowledge and aware-
ness about viral hepatitis; poor infrastructure; weak data;
inadequate infection control (including massive overuse
of injections); inadequate supplies of equipment; lack of
licensing of non-medical facilities; and difficulties in
controlling the quality of services in private sector.
Who are some of the main players?
Intergovernmental level
After years of neglect of viral hepatitis there are encour-
aging signs of movement: the disease is moving up to-
wards its deserved place on the international public
health agenda. At the same time, LMICs have to cope
with emerging communicable diseases and threats such
as Ebola, Zika and dengue, not to mention malaria and
tuberculosis, and expanding epidemics of noncommu-
nicable diseases, including obesity, as well as humanitar-
ian crises and emergencies. At the intergovernmental
level, “combat viral hepatitis” is included in target 3.3 of
the United Nations’ Sustainable Development Goal on
health. The use of the verb “combat” dismays many
hepatitis professionals, given the use of the term “elimin-
ate” for other diseases, especially as vaccination offers
the possibility of preventing hepatitis A and B and treat-
ments are available to cure hepatitis C.
WHO has drafted a global strategy to eliminate viral
hepatitis as a public health concern and has regional
plans in place; it is also supporting the development of
some national plans2 [13]. Besides its regional plan,
PAHO has its existing Revolving Funds and Strategic
Fund, which offer models for introducing vaccines.
WHO’s Regional Office for Europe is preparing to im-
plement the European Vaccine Action Plan 2016–2020,
which includes a regional goal for controlling hepatitis B
virus infection.International and national levels
Partners such as the European Centres for Disease
Prevention and Control (ECDC) and the United States
Centers for Disease Control and Prevention (CDC) are
active. For example, CDC has issued guidelines for test-
ing for chronic hepatitis B and recently recommended
that everybody in the USA born between 1945 and 1965
be screened for hepatitis C. CDC’s collaboration with
the Government of the Republic of Georgia on a project
to eliminate hepatitis C could be an example for other
LMICs. Civil society bodies such as the World Hepatitis
Alliance have been instrumental in generating pressure
on governments and international organizations as well
as delivering solid research.
National governments
Some national governments have acted strongly to tackle
viral hepatitis. Brazil and Egypt have been particularly
active at the intergovernmental level. Georgia has a State
programme of targeted treatment, a population-based
prevalence survey, and a five-year strategy and action
plan [16]. Mongolia, through its prevention, control and
elimination programme, aims to halve deaths due to
liver cancer and cirrhosis by 2020 [17, 18]. Egypt, which
has the highest reported prevalence rate of hepatitis C in
the world, introduced a national plan in 2013 and in
2015 negotiated very favourable terms for the supply of
treatments for hepatitis C [19–21]. France has a national
strategy and plan for prevention and control, with a
designated unit responsible for coordination and imple-
mentation, and, to the extent that the outcomes of nego-
tiations are in the public domain, has been very
successful in Europe in lowering the price of treatment
of hepatitis C, with further discounts if certain volume
targets are met [22, 23]. Other countries (Italy, Portugal,
Spain and Switzerland) have also negotiated discounts
but the resulting prices have not been made public.
Civil society
The Gavi, the Vaccine Alliance, a global public-private
partnership, set the standard for accelerating the intro-
duction of new and underused vaccines in many LMICs.
Its support also led to a massive drop in the price of the
pentavalent vaccine for the poorest countries over the
course of a decade. The Alliance has further goals for
strengthening the capacity of health systems, improving
the predictability and sustainability of financing for
immunization, and shaping markets in order to lower
and sustain the prices of vaccines. These goals, its vision
to see the connection between childhood health and fu-
ture economic prospects, its learning-by-doing ap-
proach, and its proven success since its inception in
2000 provide models for obtaining and sustaining lower
prices for the treatment of viral hepatitis. On the other
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on advance purchase commitments, eligibility for its sup-
port was limited in terms of a country’s income, and it re-
lied on substantial donor and private-sector funding.
Extrapolation of the model to viral hepatitis is not a given
and would need careful consideration and modifications.
UNITAID is a global health initiative, launched by the
governments of five countries in 2006 as a non-profit
organization partially financed by a small levy on airline
tickets and part of one country’s tax on CO2 emissions
from air travel. Its main focus has been on HIV/AIDS,
tuberculosis and malaria, but its strategic objectives for
2013–2016 include increasing access to treatment for
co-infections with HBV and HCV. It disburses about
US$ 200 million a year in grants. Through its mandate
to work on co-infections, and focusing on the product
rather than the disease, it does not pay for treatment
cost but it is supporting WHO’s programme to prequal-
ify medicines. In 2015, UNITAID’s Executive Board
adopted a resolution [24] supporting its need to focus
strategically on the development of better tools to diag-
nose HCV infection, in particular in cases of HIV/HCV
co-infection.
Another major player in the international public health
scene is the Global Fund to Fight AIDS, Tuberculosis
and Malaria. It annually disburses about US$ 4 billion
but faces numerous demands on its budget in the con-
text of its three priority diseases [25, 26]. Despite cogent
arguments about the similarities in disease burden of
viral hepatitis compared to that of HIV/AIDS and the
wide disparities in funding, some of its donors are said
to be urging it to resist extending its mandate to cover
viral hepatitis. Having supported much work on diagnos-
tics, the Global Fund described UNITAID as a key part-
ner and trail-blazer, in particular through working to
shape markets for new health products. By providing
evidence of success through demonstration projects,
UNITAID could make it feasible for the Global Fund to
act on the recent opening for supporting HIV/HCV co-
infections.
In various countries, both civil society and the
pharmaceutical industry have teamed with governments
to introduce prevention and control programmes. For
example, the Médecins sans Frontières’ Access Campaign
has begun screening and treatment programmes for
hepatitis B and C in the Democratic Republic of the
Congo, India (Manipur province), Myanmar and
Pakistan. The Clinton Health Access Initiative is working
with health ministries in several countries, such as
Myanmar and Rwanda, to support the introduction of
sustainable government-led programmes for treating
hepatitis C. The company MSD India initiated a
programme to educate patients and their families about
hepatitis C and to help to manage the cost of treatment;its Project Sambhav was launched in the Punjab in 2012
with two elements: disease management and micro-
financing. The Onom Foundation in Mongolia, working
closely with the national Government, has instituted a
prevention campaign that includes prevention, screening
and early diagnosis, on-site rapid testing projects, lobby-
ing, and the creation of a national database on viral
hepatitis.
The International Decision Support Initiative was
created by the UK’s National Institute for Health and
Care Excellence, with support from the UK Government,
the Bill & Melinda Gates Foundation and the Rockefeller
Foundation, in order to guide decision-makers in LMICs
to effective and efficient resource allocation strategies
for improving people’s health.
Researching existing and potential partners for pro-
jects and programmes to prevent, control and eventually
eliminate viral hepatitis as a public health problem, in-
cluding mechanisms such as technology transfer and
local production (see below) is still a long way off.
Innovative and potential new funding
mechanisms
Some current funding mechanisms and initiatives have
been extremely successful. For instance, the Gavi, the
Vaccine Alliance created innovative financing mecha-
nisms such as the International Finance Facility for Im-
munisation, which raises funds by issuing bonds in the
capital markets [27]. It was also the midwife to advance
market commitments that help the development and
manufacture of new and better vaccines for use in LMICs
by guaranteeing a market, reducing unpredictability or
volatility of demand, and increasing competition and
innovation between companies and organizations [28–30].
Advance market commitments greatly accelerated the
introduction of pneumococcal conjugate vaccine and have
the potential to dramatically accelerate the introduction of
new vaccines and technologies into LMICs. The PAHO
Revolving Fund for Vaccine Procurement, which pools the
resources of 41 countries and territories, has enabled the
procurement of supplies at the lowest prices for the whole
Region of the Americas.
The principle of financing UNITAID through a levy is
now established, even though it continues to rely on a
small number of contributors. Its success is held up as a
justification for introducing innovative financing mecha-
nisms. Indeed, UNITAID commissioned a study that
showed that a levy on financial transactions could be im-
plemented and tax thereon collected.
Integrating health care financing or non-financial
health care services (e.g. health education) into a micro-
financing institution can be an opportunity to soften fi-
nancial risks associated with poor health [31]. MSD’s
microfinancing scheme in India used a financial partner
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patients to pay for their medicines over a period of time.
It took many months to overcome the difficulties of
adapting the credit company’s criteria and patient pro-
files, introducing IT systems and getting rural customers
used to modern financial services. Yet, the scheme is re-
ported to be working. Given its very low default rate, it
might be expanded.
Health insurance is seen as a possible pathway to
pursue universal health coverage, reducing out-of-pocket
expenditures and improving access to care and financial
protection in LMICs, and several health insurance
projects have been successfully introduced [32, 33].
Many countries are using health insurance as a path to-
wards universal health coverage, but it is a partial solu-
tion not a panacea. A lesson from the HIV/AIDS
experience is that disease-specific insurance does not
work. Inclusive insurance is proposed as a means of fo-
cusing on the target population. Given that most health
costs are covered in LMICs by out-of-pocket payments,
inclusive insurance mobilizes resources, pools risks and
can promote healthy behaviours, early detection and
treatment. Private and public health insurance pro-
grammes can be complementary but need good design
and oversight in order to avoid fragmentation and exces-
sive costs. Partnerships are crucial. Abt Associates’ Inter-
national Health Division is testing plans to introduce
coverage for viral hepatitis.
A community-based alternative is the rural health
cooperative. Worldwide, about one billion people are
members of cooperatives, and more than 100 million
work in them. Health cooperatives deliver their mem-
bers in rural areas medical care that is not available
through public or private health programmes [34]. In
2003, China launched the New Rural Cooperative Med-
ical System, a system of mutual assistance for health
protection through risk pooling. The structure is man-
aged, organized and subsidized by the central, provincial
and county governments. It incorporates two major
principles: voluntary participation by the rural popula-
tion and emphasis on protection against catastrophic ill-
nesses [35].
Other potential mechanisms include social/develop-
ment investment bonds for health. Private finance initia-
tives have been largely used to improve infrastructure,
but their performance has generated a poor public
image. Apart from the bonds of the International Fi-
nance Facility for Immunisation, bonds have generally
not been applied for health improvement largely because
of the lack so far of accurate data on disease burdens
and epidemiology and the inability to monitor changes
in outcome. With advances in these areas, it is now pos-
sible to consider a bond or loan (depending on fiscal
environment) to finance preventive health, linkinggovernments, health-care providers and financial institu-
tions for piloting in different policy settings. So far,
interest in such schemes has been predominantly in
Anglo-Saxon societies.
Many companies have departments for corporate
social responsibility with whom innovative partnerships
could be forged [15, 36]; for viral hepatitis an example of
an approach could be that a pharmaceutical company
foundation subsidizes the cost of hepatitis medication
for members of a national health insurance scheme,
under which hepatitis prevention and treatment proto-
cols are tested while offered as covered services. The
partners learn together about disease burden and how to
identify/treat patients cost-effectively, although the cost-
effectiveness analyses would need to take into consider-
ation the possibility of re-infection after successful
treatment [37, 38]. There could be a sliding scale for
price of medicines based on volume, providing a shared
incentive to bring a programme to scale.
A continuing theme was the considerable scope for
increasing partnerships and multisectoral cooperation.
In 2010, the World Health Assembly passed a resolution
calling on countries to “constructively engage the private
sector in providing essential health-care services” [39,
40]. Numerous partnerships have sprung up at country
and lower levels between private sector (in particular the
pharmaceutical industry) and governments or health
care centres to finance screening and treatment. These
activities tend to be scattered and uncoordinated.
New and innovative funding is an active field of study,
not just for viral hepatitis. WHO is holding a financing
dialogue with its Member States and key non-State con-
tributors, including a focus on sustainable financing and
coordination to meet priority health needs generally in
developing countries. Overall, however, donor funding
for health is becoming increasingly scarce; add the need
for sustainable and predictable funding and the task
becomes even harder. Identifying the success factors and
obstacles for these various mechanisms would contribute
to the better definition of new funding mechanisms, as
envisaged by VHPB and the International Federation of
Pharmaceutical Manufacturers & Associations (IFPMA)
[15]. Key factors already identified include: political will
(including the will to innovate); targeting with a tight
focus (with clearly defined inputs and measurable out-
comes); and effectiveness in both financial and medical
terms of reference.
Issues and needs
The dramatic more than five-fold growth in financing
for health that began in 1991 has plateaued since 2010
[41]. Impressive gains have been made in health; these
need to be maintained, yet evidence suggests that the
priority of health is in decline. The Lancet concluded
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ment conference, held in 2015, demonstrated that
“health is no longer a priority” [42]. Health accounts for
only one of the 17 Sustainable Development Goals.
There are concerns that the level of the next replenish-
ment of the Global Fund to Fight AIDS, Tuberculosis
and Malaria might not match that of previous rounds,
and the organization is being urged to focus more on
health systems strengthening.
To pay for health, countries in receipt of official devel-
opment assistance are increasingly being asked to gener-
ate domestic funding [43]. For viral hepatitis, the
potential number of cases for prevention and treatment
is enormous, yet the area is only slowly being recognized
as a funding priority, although in most countries its fi-
nancing will face an uphill struggle against established
and new competitors for funding as well as constrained
resources. While attention currently focuses on hepatitis
C, hepatitis A, B, D and E must not be overlooked.
Health-care systems are seen as black holes for
resources, while priorities for using scarce resources are
often distorted and access to services is inequitable.
However, it seems to be less a question of whether a
country or society can pay for expensive treatments or
vaccines than whether they can successfully negotiate
discounts, alone or collaboratively. Then the issue be-
comes one of affordability rather than cost. Recent
moves in government funding of treatment of hepatitis
C suggest that decisions are increasingly being based on
affordability rather than just cost-effectiveness and
budget impact.
Much has been made in public health of the value of
cost-effectiveness analyses, and indeed they can de-
politicize issues. Although cost-effectiveness is a very im-
portant criterion, it is not the only one for hepatitis C
treatment programmes, even with forecasts of cure rates
of up to 95% within 12 weeks. Indeed, budget impact
analysis and immediate availability of funds and re-
sources are the keys to initiate sustainable programmes.
The social costs besides medical costs need much better
quantification.
The keystone of successful negotiations on the price of
treatments or vaccines for the prevention and control of
viral hepatitis is the existence of a robust national plan
and strategy. Countries that have such plans and strat-
egies have negotiated the lowest prices for treatments of
hepatitis C.
To make a future free of viral hepatitis feasible and
affordable [44], the clear message was that strategies are
needed to break the vicious circle of which action comes
first. There will not be one solution, but rather a suite of
approaches. At a time when public health policies are
shifting away from vertical programmes, is there a mis-
perception of viral hepatitis programmes as such aprogramme? One overarching solution will be to include
viral hepatitis in comprehensive universal health plans
rather than disease-specific plans. To reach WHO’s
goals, treatment and testing must be part of a compre-
hensive national hepatitis plan, in addition to vaccin-
ation, surveillance, blood safety, infection control, harm
reduction, and sexual health that are also needed to
achieve dramatic reductions in transmission and disease.
Lowering the price of medicines is important but not
the only solution. The introduction of new DAAs under-
lines the need for priority setting and the resolution of
the medical, ethical and political issues about who to
treat, when to treat, what messages to convey to people
infected with HCV, and the rationing of treatment be-
cause of cost.
In addition to affordable treatments and sufficient
budgets, simplifying, and thereby reducing the cost of,
other elements in the spectrum of care and systems,
such as diagnostic tests, will strengthen prevention and
control. The Gavi, the Vaccine Alliance’s experience pro-
vides an example of such an approach. Besides provision
of the materials for viral hepatitis care and treatment
services, the fundamental questions are how to improve
access, how to use existing staff and services to deliver
good-quality care, and how to incentivize countries to
invest in screening programmes.
Other issues arise with communication. Messages
using language and terminology that are coherent and
consistent will avoid misperceptions, stigmatization and
potential loss of credibility; for example, “elimination”,
“eradication”, “affordable”, “reasonableness”, “value” and
“fairness” need definition in the context of viral hepatitis
and public health. In addition, it is vital to tailor lan-
guage to specific audiences and target groups.
With the growing recognition globally of the import-
ance of viral hepatitis in the public health agenda, it is a
time to capitalize on enthusiasm and opportunity. Many
clinical trials of different combinations of therapies are
under way and being reported. Publications on the sub-
ject abound, including guidelines for care and treatment
and many studies of cost-effectiveness. Numerous meet-
ings have been held, including a global hepatitis summit
in Glasgow in 2015. New DAAs and combinations are
being licensed and in some cases they are also being
launched in developing countries before developed
countries.Some lessons learnt from HIV/AIDS
What is happening with the prices of medicines and
access to care, the beginnings of activism and the part-
nerships between governments, the health sector, indus-
try and financial institutions echoes the early days of
AIDS, but at an accelerated rate.
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community acceptance are crucial to efforts to raise
awareness, attract funding and implement projects or
programmes. Advocacy needs to be maintained, espe-
cially to keep viral hepatitis high on the political
agenda; if possible, champions should be identified –
whether individuals or countries (as is happening now,
as witnessed by the activities of Brazil, Egypt, Slovenia
and France). Leverage of the private sector is also a
key factor. As with AIDS, viral hepatitis cuts across
many disciplines, from tax, economics and inter-
national trade to ethics, politics and health care policy
– sectors offering sources of expertise and potential
partners.
Commitment and financing will follow only when
there is a unified strategy at the political and technical
levels, coupled with continued preparatory work and a
coalition of the willing, driven by a sense of urgency.
Services for viral hepatitis should be integrated into
other health delivery services. Optimism and persever-
ance are valuable and necessary qualities in order to en-
sure continued momentum.
The initiative launched by UNAIDS and WHO in
2003 to target treating three million people infected with
HIV in LMICs with antiretroviral medicines highlighted
the value of demonstration projects and realistic scale
up. The equivalent initiative for viral hepatitis now is to
diagnose 90% of people with chronic hepatitis, to treat
90% of those diagnosed, and to treat and cure 90% of
that group. The AIDS experience has paved the way for
introduction of new hepatitis C treatments into develop-
ing countries, and we are already seeing the pressure
resulting from introduction of generic medicines and
competition.
Not everything learnt from HIV/AIDS can be success-
fully replicated or adapted. For instance, a “risk-group
focus” is inappropriate and unhelpful; activism and advo-
cacy by celebrities are not likely to have the same impact
as in the AIDS era, − even though the same anger is
there among those without access to treatment.Conclusions
The way forward
AIDS has its International AIDS Society to coordinate
academic and research aspects; an equivalent body for
viral hepatitis could perform a similar function. The
International Decision Support Initiative could be
approached to serve as a platform for engagement of the
pharmaceutical sector and other stakeholders.
The business case for funding prevention and treat-
ment of viral hepatitis needs to be fully researched, de-
veloped and strongly made. Potential traditional funders
and new funding mechanisms need to be vigorously andthoroughly investigated and persuaded to support pre-
vention and control plans.
More pilot and demonstration projects should be
launched. Successful models (e.g. microfinancing) need
to be analysed to determine the reasons for their success
and the likelihood of their being able to be transferred
or adapted to other settings. Focusing on health technol-
ogy assessment could serve as a tool to help priority set-
ting for resource allocation.
Updated policies and guidelines will be of added value
to screening, treatment, care and disease management.
Infection control and injection safety need urgently to
be improved in some countries. And the focus on pre-
vention as treatment needs to be maintained.
A further step forward could be the creation of an alli-
ance or fund for the development of infrastructure for
viral hepatitis prevention and control, formulation of
national plans and introduction of treatment, and/or
the creation of an initial non-institutional or informal
group to undertake such work, as in the lead up to the
formation of the Gavi, the Vaccine Alliance. This is a
possible role for stakeholders such as VHPB and
IFPMA. Such a body could also aim to avoid duplication
and provide coherence to the public health approaches
through coordination of parties – from research and
work on strategy development to the organizing of fur-
ther meetings of interested parties.
In summary, recommended actions highlighted during
the meeting include:
 better definition of the burden of disease and socio-
economic costs, together with analysis of data and
trends; improved quality of data
 formulation of comprehensive policies and strategies
for prevention and control of viral hepatitis at
national level, with clear definition of objectives and
priority setting
 generation of commitment and political will through
continued advocacy, and identification of strong
leadership
 creation of an alliance or fund for the development
of infrastructure for viral hepatitis prevention and
control, formulation of national plans and
introduction of treatment, and/or the creation of an
initial non-institutional or informal group to under-
take such work
 identification of a broad base of potential partners in
an alliance or coalition to advance and coordinate
activities on prevention and control of viral hepatitis
at an international level
 research into identifying the best practices and the
success factors of (demonstration) projects,
programmes, financing mechanisms (including
private sector funding through grants, loans or
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and prevention accessibility, and stimulate further
development
Endnotes
1A positive event following the meeting was the
launch of a national policy on viral hepatitis by the
Federal Nigerian Government. National prevalence rates
of hepatitis B and C are estimated to be 11% and 2.2%
respectively. The “Prevent Hepatitis – Act Now”
programme reflects the fact that most of the predispos-
ing health risks for viral hepatitis are avoidable through
adequate awareness, behavioural change and screening
of blood for transfusion. Measures will include increased
vaccination against hepatitis B, safe injection pro-
grammes, expanded screening and treatment services,
harm reduction and moves to prevent stigmatization
and discrimination. It will be essential for adequate do-
mestic funding to be assured [45].
2Adopted after the meeting.
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